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Regulatory B (Breg) cells are immunosuppressive cells that support immunological tolerance. Through the
production of interleukin-10 (IL-10), IL-35, and transforming growth factor b (TGF-b), Breg cells suppress
immunopathology by prohibiting the expansion of pathogenic T cells and other pro-inflammatory lympho-
cytes. Recent work has shown that different inflammatory environments induce distinct Breg cell popula-
tions. Although these findings highlight the relevance of inflammatory signals in the differentiation of Breg
cells, they also raise other questions about Breg cell biology and phenotype. For example, what are the func-
tional properties and phenotype of Breg cells? Can a Breg cell arise at every stage in B cell development? Is
inflammation the primary requisite for Breg cell differentiation? Here, we use these questions to discuss the
advances in understanding Breg cell biology, with a particular emphasis on their ontogeny; we propose that
multiple Breg cell subsets can be induced in response to inflammation at different stages in development.Introduction
The hallmark of an effective immune response is inflammation.
After infection, the inflammatory response is critical for clearing
pathogens and initiating protein cascades that control wound
healing (Medzhitov, 2008). If unresolved, this inflammatory
response causes injury to host tissues, which can lead to the
development of a wide variety of immune-mediated pathologies
(Medzhitov, 2008). In the healthy individual, inflammation is
self-limiting, and resolution is controlled by the release of anti-
inflammatory mediators and cytokines, such as interleukin-10
(IL-10), produced by cells that have been termed ‘‘suppressive’’
or ‘‘regulatory’’ (Nathan and Ding, 2010). Conversely, in individ-
uals with chronic inflammation, the immune system is persis-
tently activated, often characterized by a deficiency in the
number and function of these suppressor cells in circulation
and at the site of inflammation (Nathan and Ding, 2010). Over
the past decade, a population of suppressor B cells, collectively
known as regulatory B (Breg) cells, have been associated with
the inhibition of excessive inflammation (Mauri and Bosma,
2012). The use of genetically altered mice that lack B cells
(Wolf et al., 1996), and more specifically IL-10-producing B cells
(Fillatreau et al., 2002), has shown that defective Breg cell devel-
opment and function result in chronic inflammation. This sug-
gests that these cells could be targeted therapeutically for
alleviating awide variety of immune-mediated inflammatory con-
ditions. For Breg cells to be useful therapeutically, greater clarity
regarding the phenotype, induction, and stability of these cells
in vivo is needed. Here, we will discuss the principal advances
made in our understanding of the function, phenotype, and
developmental origin of Breg cells. In particular, we will focus
on newly emerging evidence demonstrating the importance of
inflammation in the differentiation of Breg cells.
What Are the Functional Properties of Breg Cells?
A suppressive function for B cells was first postulated in the
1970s after the observation that B-cell-depleted splenocytes
were unable to suppress delayed-type hypersensitivity in guinea
pigs on adoptive transfer (Katz et al., 1974; Neta and Salvin,1974). However, the molecular or biochemical mechanism
responsible for these initial observations was never character-
ized, and the field of ‘‘suppressor’’ B cells was abandoned.
The present revival of the study of B cell suppression can be
traced back to the observation that B-cell-deficient mice were
unable to recover from experimental autoimmune encephalitis
(EAE) (Wolf et al., 1996). After this, three studies showing that
B cells could suppress inflammation by the provision of IL-10
in models of colitis (Mizoguchi et al., 2002), EAE (Fillatreau
et al., 2002), and arthritis (Mauri et al., 2003) were published.
Over the last decade, much progress has been made to charac-
terize immunosuppressive B cells, or ‘‘Breg cells,’’ leading to
more rigorous study of the multiple mechanisms they employ
to suppress pro-inflammatory responses in vivo. Primarily,
Breg cells function by skewing T cell differentiation in favor of a
regulatory phenotype in both mice (Carter et al., 2011) and hu-
mans (Flores-Borja et al., 2013). The importance of B cells in
the maintenance of the regulatory T (Treg) cell compartment
can be derived from early studies showing that Treg cells are
reduced in B-cell-deficient mMT mice (Sun et al., 2008; Tadmor
et al., 2011). Later studies have shown that mice harboring a
B-cell-specific deletion of IL-10 also display a Treg cell defi-
ciency, which is associated with an outgrowth of pro-inflamma-
tory T cells after the induction of autoimmunity (Carter et al.,
2012; Carter et al., 2011). Directly, cognate interactions between
Breg cells and T cells are thought to control Treg cell induction,
given that B cells deficient in major histocompatibility complex
class II (Yoshizaki et al., 2012) and B7 (Mann et al., 2007) do
not exhibit regulatory function (Rosser et al., 2014a). Indirectly,
Breg cells suppress the differentiation of T helper 1 (Th1) and
Th17 cells by suppressing pro-inflammatory cytokine production
by dendritic cells (Matsumoto et al., 2014; Sun et al., 2005).
In addition to expressing IL-10, Breg cells express other
immune-regulatory cytokines, including transforming growth
factor b (TGF-b) and IL-35. Through the production of TGF-b,
lipopolysaccharide (LPS)-activated B cells can induce both
apoptosis of CD4+ (Tian et al., 2001) and anergy in CD8+ (Parekh
et al., 2003) effector T cells. The identification of IL-35 as a keyImmunity 42, April 21, 2015 ª2015 Elsevier Inc. 607
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Figure 1. Functional Properties of Breg Cells
Through the production of IL-10, TGF-b, and IL-35, Breg cells can suppress
the differentiation of pro-inflammatory lymphocytes, such as tumor necrosis
factor a (TNF-a)-producing monocytes, IL-12-producing dendritic cells, Th17
cells, Th1 cells, and cytotoxic CD8+ T cells. Breg cells can also induce the
differentiation of immunosuppressive T cells, Foxp3+ T cells, and T regulatory 1
(Tr1) cells. Breg cells also support the maintenance of iNKT cells.
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recent breakthrough in the field. Chimeric mice lacking expres-
sion of IL-35 subunits, either p35 or EBi3, in B cells alone develop
exacerbated EAE and are provided with greater protection
against Salmonella-induced sepsis. In the Salmonella model,
lack of IL-35 expression by B cells resulted in enhanced Th1
cell responses and an increase in the number of macrophages
in the spleen (Shen et al., 2014). Another independent study
has shown that IL-35-stimulated B cells produce IL-35 and are
able to inhibit experimental uveitis on adoptive transfer (Wang
et al., 2014). It has also been proposed that Breg cells are critical
in maintaining invariant natural killer (iNKT) cell homeostasis in
humans (Bosma et al., 2012). These examples also show the
advancement in the understanding of the pleiotropic role of
Breg cells in the suppression of immune responses, given that
Breg cells have the capacity to target many immune-system
cells to exert suppression (Figure 1).
What Is the Phenotype of Breg Cells? Is There a Breg-
Cell-Specific Transcription Factor?
Although a partial consensus regarding the effector function of
Breg cells has been reached, the field has yet to produce a uni-
fied view concerning their phenotype. To date, multiple Breg cell
subsets with many similarities in phenotype and effector func-
tions have been described. Whether the differences observed
are due to the existence of distinct Breg cell lineages or to
changes dependent upon the immunological environment has
yet to be elucidated. In mice, multiple subsets of IL-10-produc-
ing Breg cells have been described; these include transitional 2608 Immunity 42, April 21, 2015 ª2015 Elsevier Inc.marginal-zone precursor (T2-MZP) cells (Evans et al., 2007;
Rosser et al., 2014b), CD5+CD1dhi B (B10) cells (Yanaba et al.,
2008; Yoshizaki et al., 2012), marginal-zone (MZ) B cells (Gray
et al., 2007), Tim-1+ B cells (Ding et al., 2011), CD138+ plasma
cells (Neves et al., 2010; Shen et al., 2014), and plasmablasts
(Matsumoto et al., 2014). In humans, both CD19+CD24hi
CD38hiCD1dhi (Blair et al., 2010; Flores-Borja et al., 2013) and
CD19+CD24hiCD27+ (Iwata et al., 2011) Breg cells have been
identified. The phenotypes of published Breg cell subsets and
a summary of their associated effector functions can be found
in Table 1. At present, it is unknown whether and how subsets
of Breg cells are developmentally linked.
Although the expression of IL-10 has been useful in defining
populations of suppressive B cells in mice and humans, many
surface markers that have been used for identifying Breg cells
are up- or downregulated during immune activation, leading to
inherent problems in the definition of different Breg cell subsets
among different experimental settings, which possibly accounts
for some of the discrepancies in described Breg cell subsets.
Thus, as a result of the heterogeneity of Breg cell subsets, a prin-
cipal challenge of Breg cell research has been the identification
of a Breg-cell-specific transcription factor, similar to Foxp3 in
Treg cells (Rudensky, 2011). The identification of such a mole-
cule would allow some resolution regarding the phenotype of
Breg cells and would help answer the question of whether these
cells represent a distinct lineage. To date, two models of Breg
cell development can be suggested. The first is that Breg cells,
similar to thymus-derived Treg cells, are a dedicated lineage of
B cells where a specific factor controls the expression of genes
responsible for their suppressive nature. The second is that in
response to certain stimuli, B cells take on a regulatory pheno-
type to suppress local inflammation. Despite considerable effort,
no study that has performed gene arrays on Breg cells in both
mice (Shen et al., 2014) and humans (van de Veen et al., 2013)
has conclusively identified a lineage-specific marker equivalent
to Foxp3. The inability to identify a unique transcription factor,
together with the heterogeneity of the phenotype of Breg cells,
supports the idea that suppressor B cells are not lineage specific
but rather are ‘‘reactive.’’ Thus, unlike natural Treg cells, any B
cell might potentially differentiate into a ‘‘Breg’’ cell in response
to the right environmental stimuli.
Can Breg Cells Arise at Every Stage of B cell
Development?
A recent publication demonstrating that, in addition to previously
described Breg cell subsets, plasmablasts can also suppress in-
flammatory responses supports the proposal that any B cell has
the potential to differentiate into a Breg cell; mice whose B cells
are deficient in Irf4 and Prdm1, genes necessary for plasma cell
differentiation, develop exacerbated EAE (Matsumoto et al.,
2014). This is not the first time that antibody-producing B cells
have been attributed with regulatory function: CD138+ plasma
cells that produce IL-10 and IL-35 suppress pro-inflammatory
responses during EAE and Salmonella infection (Shen et al.,
2014). Furthermore, an earlier report suggested that splenic
B10 cells have the propensity to differentiate into antibody-pro-
ducing plasmablasts after stimulation in vivo and in vitro
(Maseda et al., 2012). Matsumoto et al. also suggest a develop-
mental link between CD19+CD24hiCD38hi B cells, previously
Table 1. Different Breg Cell Subsets
Type of
Breg Cell Mouse Human Key Features Reference
T2-MZP cells CD19+CD21hi
CD23hiCD24hi
– found in spleen, produce IL-10, induce
Treg cells, and suppress effector CD4+
and CD8+ T cells
Blair et al., 2009; Carter et al., 2011;
Evans et al., 2007; Schioppa et al., 2011
MZ cells CD19+CD21hi
CD23
– found in spleen, produce IL-10, induce
Treg cells, and suppress effector CD4+
and CD8+ T cells
Bankoti et al., 2012; Gray et al., 2007;
Miles et al., 2012
B10 cells CD5+CD1dhi CD24hiCD27+ found in spleen (mice) and blood (humans),
produce IL-10, and suppress effector CD4+
T cells, monocytes, and DCs
Horikawa et al., 2013; Iwata et al., 2011;
Matsushita et al., 2010; Yanaba et al., 2008
Plasma cells CD138+MHC-11lo
B220+
– found in spleen, produce IL-10 and IL-35,
and suppress NK cells, neutrophils, and
effector CD4+ T cells
Neves et al., 2010; Shen et al., 2014
Tim-1+ B cells Tim-1+CD19+ – found in spleen (mice), produce IL-10,
and suppress effector CD4+ T cells
Ding et al., 2011; Xiao et al., 2012
Plasmablasts CD138+CD44hi CD19+CD24hi
CD27int
found in dLNs (mice) and blood (humans),
produce IL-10, and suppress DCs and
effector CD4+ T cells
Matsumoto et al., 2014
Immature cells – CD19+CD24hi
CD38hi
found in blood and at site of inflammation,
produce IL-10, induce Treg cells, suppress
Th1 and Th17 cells, suppress virus-specific
CD8+ T cell responses, are defective in
patients with SLE and RA, and support iNKT
cell homeostasis
Blair et al., 2010; Bosma et al., 2012;
Das et al., 2012; Flores-Borja et al., 2013
Br1 cells – CD19+CD25hi
CD71hi
found in blood and produce IL-10 and IgG4 van de Veen et al., 2013
This table shows currently described subsets of Breg cells in mice and humans. Abbreviations are as follows: Br1, B regulatory 1; DC, dendritic cell;
dLN, draining lymph node; IgG4, immunoglobulin G4; MHC, major histocompatibility complex; MZ, marginal zone; NK, natural killer; RA, rheumatoid
arthritis; SLE, systemic lupus erythematosus; T2-MZP, transitional 2 marginal-zone precursor.
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IL-10-producing plasmablasts in humans. This suggests that a
similar fate—the development into plasma cells—exists for
Breg cells in both mice and humans (Matsumoto et al., 2014).
The idea that antibody-producing B cells are also regulators of
immune responses is hard to reconcile with current knowledge
that plasma cells drive inflammatory responses through the pro-
duction of antibody, which is often pathogenic in the context of
autoimmunity or allergy. Thus, it might be possible that a subset
of plasmablasts maintain the ability to regulate inflammatory
responses while producing antibody. This is supported by data
showing that the lack ofBcl6 has no effect on regulatory plasma-
blast generation (Matsumoto et al., 2014), which is known to be
important for the expansion of class-switched cells through B
cell proliferation in germinal centers (Dent et al., 1997), suggest-
ing that regulatory plasmablasts are contained within an immu-
noglobulin-M-positive subset (Matsumoto et al., 2014).
Taking into account these latest studies, it has now been
demonstrated that immature B cells, mature B cells, and plas-
mablasts all have the capacity to differentiate into IL-10-produc-
ing Breg cells in both mice and humans. This supports the
concept that the primary requisite for Breg cell differentiation is
not the expression of a Breg-cell-specific lineage factor but
rather the environment in which a B cell finds itself. With this
in mind, the identification of stimuli necessary to induce B cells
to become regulatory is an important consideration in the
assessment of the origin of Breg cells. Toll-like receptor (TLR)and/or CD40 activation is the most well-characterized signal
known to induce their differentiation (reviewed in Mauri and
Bosma, 2012). However, a spate of recent publications has
revealed that pro-inflammatory cytokines can also drive the
induction of IL-10-producing Breg cells.
Is Inflammation the Primary Requisite for the
Differentiation of Breg Cells?
There is strong evidence that the number and suppressive ability
of Breg cells increase in response to inflammation. For example,
although they are present in naive mice, Breg cells increase in
number during the inflammatory phase of several autoimmune
disorders (Evans et al., 2007; Mizoguchi et al., 2002). Moreover,
it is known that Breg cells are functionally suppressive in the in-
flammatory phase of autoimmunity, given that in their absence,
mice develop exacerbated arthritis or unremitting EAE (Carter
et al., 2012; Carter et al., 2011; Fillatreau et al., 2002). This sug-
gests that Breg cells are activated in response to the same
inflammatory signals that drive autoimmune disease and thus
limit damaging inflammation that would otherwise develop.
Recently, it was demonstrated that Breg cells arise in response
to IL-1b and IL-6, pro-inflammatory cytokines that are produced
after the induction of antigen-induced arthritis (Rosser et al.,
2014b). The production of these cytokines in arthritic mice is
controlled by the community of bacteria in the gut, collectively
known as the microbiota, a pathway that has been previously
shown to induce the differentiation of pro-arthritogenic Th17Immunity 42, April 21, 2015 ª2015 Elsevier Inc. 609
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Figure 2. Proposed Developmental
Pathways for Breg Cell Differentiation
After CD40 activation, TLR activation, or activation
with cytokines, immature B cells can differentiate
into B10 cells, IL-10-producing T2-MZP cells, and
mature B cells. It is possible that while B10 and T2-
MZP cells are differentiating into plasmablasts
and/or plasma cells, they retain their ability to
produce IL-10 and/or IL-35. B10 and T2-MZP cells
can also differentiate into mature B cells. IL-10-
and/or IL-35-producing plasmablasts and/or
plasma cells can also develop directly frommature
B cells. All Breg cell types can terminally differ-
entiate into antibody-producing plasma cells.
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sion on B cells, mice housed in non-sterile conditions develop
exacerbated arthritis (Rosser et al., 2014b). Thus, perhaps
Breg cells are expanded in response to IL-1b and IL-6 in order
to keep the immune system in check, preventing the uncon-
trolled expansion of pro-inflammatory lymphocytes such as
Th17 cells. Other inflammatory cytokines that are known to be
critical for Th17 cell differentiation, such as IL-21 (Yoshizaki
et al., 2012) and granulocyte macrophage colony-stimulating
factor (GM-CSF, in combination with IL-15) (Rafei et al., 2009),
have also been shown to be important in Breg cell differentiation.
Importantly, different cellular sources of the cytokines that can
induce IL-10 production by B cells have been identified.
Myeloid-derived cells producing IL-6 (in the mesenteric lymph
nodes) and both IL-6 and IL-1b (in the spleen) are responsible
for Breg cell induction in arthritis (Rosser et al., 2014b), whereas
IL-21-producing CD4+ T cells located in the spleen are respon-
sible for Breg cell induction in EAE (Yoshizaki et al., 2012).
Conversely, it has been reported that treatment of mice with
the anti-inflammatory cytokine IL-35 induces a population of
IL-10- and IL-35-expressing B cells and thus suppresses the
development of uveitis (Wang et al., 2014). This suggests that
anti-inflammatory cytokines might also have a role in Breg cell
differentiation. However, there is evidence suggesting that
IL-35 is not constitutively expressed but is induced in response
to inflammation (Li et al., 2012).
Although non-cognate inflammatory stimuli, e.g., IL-1b, IL-6,
and IL-21, are clearly important in the generation of Breg cells,
it should not be forgotten that evidence suggests that B cell
receptor (BCR) recognition is important in Breg cell induction. In
MD4 mice, where the BCR is fixed for an irrelevant antigen,
Breg cell activation is impaired; bone marrow chimeras that
have MD4 B cells are unable to resolve EAE (Fillatreau et al.,
2002), and MD4 mice produce less B-cell-derived IL-10 in
response to TLR-9 activation (Miles et al., 2012) and have fewer
B10 cells than do wild-type mice (Yanaba et al., 2009). Further
evidence of the importance of BCR recognition in Breg cell
function has been provided by experiments utilizing mice with
a B-cell-specific deletion of stromal interaction molecule 1
(STIM-1) andSTIM-2. STIM-1 andSTIM-2are important formedi-
ating the influx of calcium into the B cell cytosol from outside the
cell after antigen recognitionof theBCR.Mice lackingSTIM-1and
STIM-2 exclusively on B cells produce less IL-10 after stimulation
with the auto-antigen MOG and anti-CD40 (Matsumoto et al.,610 Immunity 42, April 21, 2015 ª2015 Elsevier Inc.2011). Taken together, these data show that antigen-specific
recognition by the BCR is important for Breg cell function and
development, but it is still not clearwhetherBregcells are reactive
to the auto-antigens or putative endogenous ligands. Thus, in
response to BCR recognition and inflammation, B cells might
differentiate into both regulatory and antibody-producing cells.
The importance of inflammation in the differentiation of Breg
cells calls into question the location of their maturation. To
date, most studies have characterized splenic populations of B
cells. However, other publications have reported that Breg cells
are found in the lymph node draining the site of inflammation
after the development of colitis (Mizoguchi et al., 2002) and
EAE (Matsumoto et al., 2014). Importantly, the study in EAE by
Matsumoto et al. (2014) demonstrates that Breg cells can
develop and acquire their suppressive capabilities outside the
spleen, in the draining lymph node, given that splenectomy has
no effect on their generation. This supports the idea that the in-
duction of Breg cells is dictated by inflammatory environment
but is at odds with previously published data characterizing the
spleen as the primary location for Breg cell development.
Breg Cells: What Next?
Although it cannot be ruled out that a transcriptional regulator
that defines Breg cell function might be discovered in the future,
at present there is no evidence to support this model. Thus, on
the basis of the idea that Breg cells are not lineage specific but
rather are expanded in response to inflammation, different
models can be suggested for their development. These include
the proposal that Breg cells are short-lived effector cells that
are expanded in response to inflammation or, alternatively, that
Breg cells are an inflammation-inducible subset that enters a
further differentiation pathway after the resolution of an inflam-
matory responses, such as the maturation of immature B cells
into plasmablasts. There is evidence for both hypotheses, yet
without the development of a fate reporter mouse that allows
the identification of the historical expression of IL-10, it is
currently not possible to be certain exactly what happens to a
Breg cell after the cessation of an inflammatory response.
Thus, at the moment, more questions have been raised than
answered. For example, is the acquisition of regulatory function
tissue dependent? Do certain stimuli direct B cells to traffic to the
site of inflammation? Can we separate the stimuli necessary to
induce the differentiation of antibody-producing and regulatory
B cells? We believe that it is these questions that need to be
Immunity
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therapeutically.
Concluding Remarks
Experimental evidence concerning the role of Breg cells in the
suppression of inflammatory responses has been confused by
the description of multiple Breg cell subsets. We propose that
immunosuppression is not the purview of a devoted Breg cell
lineage with a specific phenotype but rather is the outcome of
the dynamic balance between multiple B cell subsets and other
cells of the immune system. This hypothesis is supported by
recent data underlining the importance of inflammatory cyto-
kines in the induction of Breg cells, suggesting that Breg cells
arise in response to inflammation, when immunosuppression is
most needed. More recent publications suggest a develop-
mental link between B cell subsets previously ascribed a regula-
tory phenotype and antibody-producing B cells, suggesting that
although Breg cells might be inducible from multiple develop-
mental stages, they might all share the capacity to become
terminally differentiated plasma cells (Figure 2). In conclusion,
although the Breg cell field has in the last year made many
advances regarding the biological processes that control Breg
cell differentiation, more resolution is needed before we can fully
understand what happens during the life cycle of a Breg cell
in vivo.
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